Chemokine network inhibitor platform: The network is the target
Inspired by evasins, naturally occurring tick proteins that bind and neutralise multiple chemokines, Oxford researchers have developed a peptide engineering platform that selectively targets and neutralises multiple chemokines, offering a new approach to modulating inflammatory signalling.
Applications: Cardiovascular inflammation, atherosclerosis, type 1 diabetes and other immune-mediated inflammatory diseases
| Features | Benefits |
|---|---|
| Targets multiple chemokines within disease-relevant networks | Addresses the functional redundancy of the chemokine system |
| Inspired by tick-derived evasins | Exploits a naturally evolved mechanism for binding and neutralising multiple chemokines |
| Engineered peptide inhibitorsEngineered peptide inhibitors | Enables generation of candidates with defined chemokine-network selectivity |
| Network-level discovery and optimisation | Provides a reusable platform for developing and refining inhibitors for different inflammatory indications |
| Lead candidates with complementary activity profiles | Enables development of broader or more selective approaches to modulating immune-cell recruitment, including the lead candidates TRAFITIDE and LEUFITIDE |
| Modular therapeutic platform | Provides opportunities to optimise pharmacokinetics, stability and tissue localisation while preserving chemokine-network selectivity |
| Protected intellectual property | Peptide candidates protected under patent application WO 2024/003555 |
Patented and Available For
- Co-development
- Consulting
- Licensing